Vaccines, Immunotherapy and New Antifungal Therapy Against Fungi: Updates in the New Frontier
Invasive fungal diseases have increased many fold over the past 50 years. Current treatment regimens typically require prolonged administration of antifungal medications that can have significant toxicity. Moreover, our present potent antifungal armamentarium fails to eradicate fungal pathogens from...
Saved in:
Superior document: | Frontiers Research Topics |
---|---|
: | |
Year of Publication: | 2017 |
Language: | English |
Series: | Frontiers Research Topics
|
Physical Description: | 1 electronic resource (183 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993543792804498 |
---|---|
ctrlnum |
(CKB)4100000002484751 (oapen)https://directory.doabooks.org/handle/20.500.12854/61823 (EXLCZ)994100000002484751 |
collection |
bib_alma |
record_format |
marc |
spelling |
Carlos P. Taborda auth Vaccines, Immunotherapy and New Antifungal Therapy Against Fungi: Updates in the New Frontier Vaccines, Immunotherapy and New Antifungal Therapy Against Fungi Vaccines; Immunotherapy and New Antifungal Therapy Against Fungi Frontiers Media SA 2017 1 electronic resource (183 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers Research Topics Invasive fungal diseases have increased many fold over the past 50 years. Current treatment regimens typically require prolonged administration of antifungal medications that can have significant toxicity. Moreover, our present potent antifungal armamentarium fails to eradicate fungal pathogens from certain compromised hosts. Additionally, invasive fungal diseases continue to have unacceptably high mortality rates. A growing body of work has focused on the utility of vaccines and/or immunotherapy as a powerful tool in combating mycoses, either for the active treatment, as an adjuvant, or in the prevention of specific fungal pathogens. Also, it is growing the interest over new drugs development as second choice for treatment when traditional chemotherapy fail. This Research Topic will detail the exciting progress in developing vaccines, immunotherapy and new drugs for fungi. English antifugal drugs vaccine peptide antibody virulence fungi immunotherapy humanized antibody mycosis cell biology 2-88945-327-8 Joshua D. Nosanchuk auth |
language |
English |
format |
eBook |
author |
Carlos P. Taborda |
spellingShingle |
Carlos P. Taborda Vaccines, Immunotherapy and New Antifungal Therapy Against Fungi: Updates in the New Frontier Frontiers Research Topics |
author_facet |
Carlos P. Taborda Joshua D. Nosanchuk |
author_variant |
c p t cpt |
author2 |
Joshua D. Nosanchuk |
author2_variant |
j d n jdn |
author_sort |
Carlos P. Taborda |
title |
Vaccines, Immunotherapy and New Antifungal Therapy Against Fungi: Updates in the New Frontier |
title_full |
Vaccines, Immunotherapy and New Antifungal Therapy Against Fungi: Updates in the New Frontier |
title_fullStr |
Vaccines, Immunotherapy and New Antifungal Therapy Against Fungi: Updates in the New Frontier |
title_full_unstemmed |
Vaccines, Immunotherapy and New Antifungal Therapy Against Fungi: Updates in the New Frontier |
title_auth |
Vaccines, Immunotherapy and New Antifungal Therapy Against Fungi: Updates in the New Frontier |
title_alt |
Vaccines, Immunotherapy and New Antifungal Therapy Against Fungi Vaccines; Immunotherapy and New Antifungal Therapy Against Fungi |
title_new |
Vaccines, Immunotherapy and New Antifungal Therapy Against Fungi: Updates in the New Frontier |
title_sort |
vaccines, immunotherapy and new antifungal therapy against fungi: updates in the new frontier |
series |
Frontiers Research Topics |
series2 |
Frontiers Research Topics |
publisher |
Frontiers Media SA |
publishDate |
2017 |
physical |
1 electronic resource (183 p.) |
isbn |
2-88945-327-8 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT carlosptaborda vaccinesimmunotherapyandnewantifungaltherapyagainstfungiupdatesinthenewfrontier AT joshuadnosanchuk vaccinesimmunotherapyandnewantifungaltherapyagainstfungiupdatesinthenewfrontier AT carlosptaborda vaccinesimmunotherapyandnewantifungaltherapyagainstfungi AT joshuadnosanchuk vaccinesimmunotherapyandnewantifungaltherapyagainstfungi |
status_str |
n |
ids_txt_mv |
(CKB)4100000002484751 (oapen)https://directory.doabooks.org/handle/20.500.12854/61823 (EXLCZ)994100000002484751 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
Frontiers Research Topics |
is_hierarchy_title |
Vaccines, Immunotherapy and New Antifungal Therapy Against Fungi: Updates in the New Frontier |
container_title |
Frontiers Research Topics |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1787548770184986624 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02213nam-a2200421z--4500</leader><controlfield tag="001">993543792804498</controlfield><controlfield tag="005">20231214133246.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2017 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4100000002484751</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/61823</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994100000002484751</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Carlos P. Taborda</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Vaccines, Immunotherapy and New Antifungal Therapy Against Fungi: Updates in the New Frontier</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Vaccines, Immunotherapy and New Antifungal Therapy Against Fungi</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Vaccines; Immunotherapy and New Antifungal Therapy Against Fungi</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (183 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Invasive fungal diseases have increased many fold over the past 50 years. Current treatment regimens typically require prolonged administration of antifungal medications that can have significant toxicity. Moreover, our present potent antifungal armamentarium fails to eradicate fungal pathogens from certain compromised hosts. Additionally, invasive fungal diseases continue to have unacceptably high mortality rates. A growing body of work has focused on the utility of vaccines and/or immunotherapy as a powerful tool in combating mycoses, either for the active treatment, as an adjuvant, or in the prevention of specific fungal pathogens. Also, it is growing the interest over new drugs development as second choice for treatment when traditional chemotherapy fail. This Research Topic will detail the exciting progress in developing vaccines, immunotherapy and new drugs for fungi.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antifugal drugs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">vaccine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">peptide</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antibody</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">virulence</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fungi</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">humanized antibody</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mycosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cell biology</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88945-327-8</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Joshua D. Nosanchuk</subfield><subfield code="4">auth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:48:08 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2018-03-10 17:16:05 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337400400004498&Force_direct=true</subfield><subfield code="Z">5337400400004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337400400004498</subfield></datafield></record></collection> |